Clinical Trial Update: First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing EN3348 (MCC) with BCG for non-muscle invasive bladder cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• BCG (Bacillus Calmette-Guérin)
• EN3348 (MCC) (EN3348)

Snippet

Sponsor: Bioniche Life Sciences Inc. | Conditions: Bladder Cancer | Phase 3 | Status: WITHDRAWN